These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 31200832)

  • 21. Gefitinib Versus Adjuvant Chemotherapy in Patients With Stage II-IIIA Non-Small-Cell Lung Cancer Harboring Positive EGFR Mutations: A Single-Center Retrospective Study.
    Xie H; Wang H; Xu L; Li M; Peng Y; Cai X; Feng Z; Ren W; Peng Z
    Clin Lung Cancer; 2018 Nov; 19(6):484-492. PubMed ID: 30369426
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adjuvant chemotherapy following stereotactic body radiotherapy for early stage non-small-cell lung cancer is associated with lower overall: A National Cancer Database Analysis.
    Foster CC; Rusthoven CG; Sher DJ; Feldman L; Pasquinelli M; Spiotto MT; Koshy M
    Lung Cancer; 2019 Apr; 130():162-168. PubMed ID: 30885339
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concurrent Versus Sequential Chemoradiation Therapy in Completely Resected Pathologic N2 Non-Small Cell Lung Cancer: Propensity-Matched Analysis of the National Cancer Data Base.
    Moreno AC; Haque W; Verma V; Fang P; Lin SH
    Ann Surg Oncol; 2018 May; 25(5):1245-1253. PubMed ID: 29484562
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of Survival Rates After a Combination of Local Treatment and Systemic Therapy vs Systemic Therapy Alone for Treatment of Stage IV Non-Small Cell Lung Cancer.
    Uhlig J; Case MD; Blasberg JD; Boffa DJ; Chiang A; Gettinger SN; Kim HS
    JAMA Netw Open; 2019 Aug; 2(8):e199702. PubMed ID: 31433481
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lobectomy versus sublobar resection for stage I (T1-T2aN0M0) small cell lung cancer: A SEER population-based propensity score matching analysis.
    Zhou N; Yang L; Zhang B; Zhu S; Huo H; He J; Zu L; Song Z; Xu S
    Cancer Med; 2023 Apr; 12(7):7923-7931. PubMed ID: 36567517
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant chemotherapy for elderly patients with non-small-cell lung cancer.
    Yamanashi K; Okumura N; Yamamoto Y; Takahashi A; Nakashima T; Matsuoka T; Kameyama K
    Asian Cardiovasc Thorac Ann; 2017 Jun; 25(5):371-377. PubMed ID: 28592139
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adjuvant Chemotherapy for the Completely Resected Stage IB Nonsmall Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    He J; Shen J; Yang C; Jiang L; Liang W; Shi X; Xu X; He J
    Medicine (Baltimore); 2015 Jun; 94(22):e903. PubMed ID: 26039122
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic significance and adjuvant chemotherapy survival benefits of a solid or micropapillary pattern in patients with resected stage IB lung adenocarcinoma.
    Qian F; Yang W; Wang R; Xu J; Wang S; Zhang Y; Jin B; Yu K; Han B
    J Thorac Cardiovasc Surg; 2018 Mar; 155(3):1227-1235.e2. PubMed ID: 29223834
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of thymosin α1 as an immunomodulatory therapy on long-term survival of non-small cell lung cancer patients after R0 resection: a propensity score-matched analysis.
    Guo CL; Mei JD; Jia YL; Gan FY; Tang YD; Liu CW; Zeng Z; Yang ZY; Deng SY; Sun X; Liu LX
    Chin Med J (Engl); 2021 Nov; 134(22):2700-2709. PubMed ID: 34732663
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment patterns and clinical outcomes of patients with resectable non-small cell lung cancer receiving neoadjuvant immunochemotherapy: A large-scale, multicenter, real-world study (NeoR-World).
    Yang Z; Wang S; Yang H; Jiang Y; Zhu L; Zheng B; Fu H; Ma J; Xie H; Wang Z; He H; Xia C; Li R; Xu J; Han J; Huang X; Li Y; Zhao B; Ni C; Xing H; Chen Y; Wang J; Jiang Y; Song Y; Mao Y; Chen C; Yao F; Zhang G; Hu J; Xue Q; Gao S; He J;
    J Thorac Cardiovasc Surg; 2024 Oct; 168(4):1245-1258.e17. PubMed ID: 38342430
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adjuvant Chemotherapy Improves the Probability of Freedom From Recurrence in Patients With Resected Stage IB Lung Adenocarcinoma.
    Hung JJ; Wu YC; Chou TY; Jeng WJ; Yeh YC; Hsu WH
    Ann Thorac Surg; 2016 Apr; 101(4):1346-53. PubMed ID: 26794883
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjuvant chemotherapy may improve long-term outcomes in stage IB non-small cell lung cancer patients with previous malignancies: A propensity score-matched analysis.
    Zhou K; Zhao Y; Liang L; Cao J; Lin H; Peng Z; Mei J
    Front Oncol; 2022; 12():938195. PubMed ID: 36119504
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Propensity score-matched analysis of adjuvant chemotherapy for stage I non-small cell lung cancer.
    Tsutani Y; Miyata Y; Kushitani K; Takeshima Y; Yoshimura M; Okada M
    J Thorac Cardiovasc Surg; 2014 Oct; 148(4):1179-85. PubMed ID: 25112928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Effect of Adjuvant Chemotherapy on DFS for Patients with Stage I NSCLC].
    Peng S; Li X; Wang Y; Liu J
    Zhongguo Fei Ai Za Zhi; 2017 Jul; 20(7):485-489. PubMed ID: 28738965
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stage IA non-small cell lung cancer: vessel invasion is a poor prognostic factor and a new target of adjuvant chemotherapy.
    Tsuchiya T; Akamine S; Muraoka M; Kamohara R; Tsuji K; Urabe S; Honda S; Yamasaki N
    Lung Cancer; 2007 Jun; 56(3):341-8. PubMed ID: 17350137
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Benefits of adjuvant chemotherapy in elderly patients with stage IB-IIIB non-small cell lung cancer: a propensity-matched analysis.
    Qin X; Xiao X; Xia H; Yang K; Zhang S
    Transl Cancer Res; 2024 Jun; 13(6):3003-3015. PubMed ID: 38988934
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is adjuvant chemotherapy for completely resected p-stage IA (>2 cm) and stage IB non-small-cell lung cancer beneficial for elderly patients? A large, retrospective cohort study based on real-world data from Japan.
    Adachi H; Saito A; Shintani Y; Okami J; Ito H; Ohtsuka T; Mori T; Watanabe SI; Chida M; Endo S; Nakanishi R; Kadokura M; Suzuki H; Miyaoka E; Yoshino I; Date H; Japanese Joint Committee Of Lung Cancer Registry
    Jpn J Clin Oncol; 2023 Dec; 53(12):1191-1200. PubMed ID: 37626449
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sublobar resection compared with stereotactic body radiation therapy and ablation for early stage non-small cell lung cancer: A National Cancer Database study.
    Wu J; Bai HX; Chan L; Su C; Zhang PJ; Yang L; Zhang Z
    J Thorac Cardiovasc Surg; 2020 Nov; 160(5):1350-1357.e11. PubMed ID: 32033815
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjuvant Chemotherapy for Patients with T2N0M0 NSCLC.
    Morgensztern D; Du L; Waqar SN; Patel A; Samson P; Devarakonda S; Gao F; Robinson CG; Bradley J; Baggstrom M; Masood A; Govindan R; Puri V
    J Thorac Oncol; 2016 Oct; 11(10):1729-35. PubMed ID: 27287414
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advantage of post-operative oral administration of UFT (tegafur and uracil) for completely resected p-stage I-IIIa non-small cell lung cancer (NSCLC).
    Tanaka F; Miyahara R; Ohtake Y; Yanagihara K; Fukuse T; Hitomi S; Wada H
    Eur J Cardiothorac Surg; 1998 Sep; 14(3):256-62; discussion 263-4. PubMed ID: 9761434
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.